Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy - Capricor Therapeutics
Capricor Therapeutics’ Deramiocel for Duchenne muscular dystrophy fell after an FDA advisory panel voted 9-3 that the company did not provide sufficient evidence of effectiveness. FDA staff cited lack of substantial evidence from Study HOPE-3 and no significant differences vs placebo in HOPE-2. Capricor noted The Lancet published HOPE-3 results. Shares were down 52.36% to $3.13.
How this was made
The 30-second read
Why it matters
The advisory panel’s 9-3 vote that evidence is insufficient materially increases perceived approval risk, and the article ties the rejection to specific efficacy evidence gaps across HOPE-2 and HOPE-3 endpoints.
Market read
This is a direct regulatory catalyst for CAPR, with a decisive advisory panel vote and a clear timeline into the Aug 22 FDA action date.
What to watch
The article emphasizes panel concerns and staff briefing, but does not detail whether the FDA will weigh the peer-reviewed HOPE-3 findings differently or whether additional analyses could be accepted before the PDUFA date.
Background
Capricor’s Deramiocel is being evaluated for Duchenne muscular dystrophy (DMD), with FDA staff briefing documents and an advisory panel vote preceding the PDUFA decision.
Ticker impact
FDA advisory panel voted 9-3 that Capricor failed to provide sufficient evidence of Deramiocel effectiveness for DMD, echoing staff concerns.
Further volatility and downside bias are likely as traders price a higher probability of an FDA non-approval or additional data requests.
The article cites a decisive 9-3 panel vote against efficacy evidence and notes FDA staff concerns about post hoc analysis changes, which typically increases near-term approval risk.
Market effects
Highlights heightened FDA scrutiny of post hoc analysis and statistical interpretation in late-stage gene/cell therapy efficacy claims.
Limited direct regional spillover expected beyond US biotech sentiment.
Could influence global investor risk appetite for DMD cell therapy programs and similar efficacy-evidence standards.
Counterpoint
A Lancet publication and peer-reviewed HOPE-3 results may support an argument that the FDA panel undervalued clinical relevance, leaving room for a different FDA final decision.
Key entities
- companyCapricor Therapeutics
Subject of the article; shares fell sharply after the FDA advisory panel rejected the evidence for Deramiocel effectiveness.
- productDeramiocel
Capricor’s Duchenne cell therapy whose effectiveness evidence was questioned by the FDA advisory panel.
- regulatorFDA Advisory Panel
Voted 9-3 that Capricor failed to provide sufficient evidence supporting Deramiocel effectiveness.
- clinical_trialStudy HOPE-3
Phase 3 trial results described as small and variable with measures not reaching statistical significance.
- clinical_trialStudy HOPE-2
Did not show statistically significant treatment differences versus placebo on key upper limb and cardiac MRI findings.
